Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Muller P, Woods L, Walters S. Temporal and geographic changes in stage at diagnosis in England during 2008-2013: a population-based study of colorectal, lung and ovarian cancers. Cancer Epidemiol. 2020;67:101743. doi:10.1016/j.canep.2020.101743
   PubMed Web of Science ®Google Scholar
• Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004;91(11):1931–1946. doi:10.1038/sj.bjc.6602215
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea E, Martinez-Cardus A, Gines A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14(8):1767–1776. doi:10.1158/1535-7163.MCT-14-0636
   PubMed Web of Science ®Google Scholar
• Prutianu I, Alexa-Stratulat T, Cristea EO, et al. Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: practical lessons from a prospective cross-sectional, real-world study. World J Clin Cases. 2022;10(10):3101–3112. doi:10.12998/wjcc.v10.i10.3101
   PubMed Web of Science ®Google Scholar
• Wei G, Gu Z, Gu J, et al. Platinum accumulation in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst. 2021;26(1):35–42. doi:10.1111/jns.12432
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ. Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines. Int J Mol Sci. 2019;20(15):5676.
   PubMed Web of Science ®Google Scholar
• Almeida LO, Neto PC, Sousa M. SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget. 2017;8(16):26802–26818. doi:10.18632/oncotarget.15818
   PubMedGoogle Scholar
• Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016;6:56.
   Web of Science ®Google Scholar
• Lee SH, Yoo C, Im S, Jung JH, Choi HJ, Yoo J. Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance. Int J Med Sci. 2014;11(10):994–1000. doi:10.7150/ijms.8522
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669–1677. doi:10.1158/1078-0432.CCR-07-0990
   PubMed Web of Science ®Google Scholar
• Liu C, Lv D, Li M, et al. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer. Int J Oncol. 2017;50(6):2079–2090. doi:10.3892/ijo.2017.3967
   PubMed Web of Science ®Google Scholar
• Linares A, Assou S, Lapierre M, et al. Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers. Mol Oncol. 2019;13(7):1534–1547. doi:10.1002/1878-0261.12505
   PubMed Web of Science ®Google Scholar
• Ler SY, Leung CH, Khin LW, et al. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep. 2015;34(5):2238–2250. doi:10.3892/or.2015.4263
   PubMed Web of Science ®Google Scholar
• Minamiya Y, Ono T, Saito H, et al. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol. 2010;31(5):533–539. doi:10.1007/s13277-010-0066-0
   PubMedGoogle Scholar
• Zhang K, Liu Z, Yao Y, et al. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC). J Med Chem. 2021;64(7):4020–4033. doi:10.1021/acs.jmedchem.0c02161
   PubMed Web of Science ®Google Scholar
• Jordaan G, Liao W, Sharma S. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC Cancer. 2013;13:67.
   PubMed Web of Science ®Google Scholar
• Shankar E, Pandey M, Verma S, et al. Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. Mol Carcinog. 2020;59(8):955–966. doi:10.1002/mc.23214
   PubMed Web of Science ®Google Scholar
• Xie Y, Tang P, Xing X, et al. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2020;241:118669. doi:10.1016/j.saa.2020.118669
   PubMed Web of Science ®Google Scholar
• Liu L, Chen B, Qin S, et al. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun. 2010;392(2):190–195. doi:10.1016/j.bbrc.2010.01.011
   PubMed Web of Science ®Google Scholar
• Wang H, Liu YC, Zhu CY, et al. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. J Exp Clin Cancer Res. 2020;39(1):278. doi:10.1186/s13046-020-01792-8
   PubMed Web of Science ®Google Scholar
• Que Y, Zhang XL, Liu ZX, et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 2021;9(2):98.
   Web of Science ®Google Scholar
• Tu K, Yu Y, Wang Y, et al. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade. ACS Appl Mater Interfaces. 2021;13(33):39003–39017. doi:10.1021/acsami.1c08290
   PubMed Web of Science ®Google Scholar
• He Y, Jiang D, Zhang K, et al. Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy. J Cancer. 2021;12(20):6198–6208. doi:10.7150/jca.61602
   PubMed Web of Science ®Google Scholar
• Ding N, You A, Tian W, Gu L, Deng D. Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16(14):2595–2611. doi:10.7150/ijbs.45886
   PubMed Web of Science ®Google Scholar
• Li X, Yuan X, Wang Z, et al. Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells. Front Oncol. 2022;12:819714. doi:10.3389/fonc.2022.819714
   PubMed Web of Science ®Google Scholar
• Liu L, Qiu S, Liu Y, et al. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. Neoplasma. 2016;63(2):193–200. doi:10.4149/203_150422N214
   PubMed Web of Science ®Google Scholar
• Zhou Y, Pan DS, Shan S, et al. Non-toxic dose chidamide synergistically enhances platinum- induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483–491. doi:10.1016/j.biopha.2014.03.011
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.10
   PubMed Web of Science ®Google Scholar
• Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110. doi:10.1016/j.crphar.2022.100110
   PubMedGoogle Scholar
• Barnard GF, Mori M, Staniunas RJ, et al. Ubiquitin fusion proteins are overexpressed in colon cancer but not in gastric cancer. Biochim Biophys Acta. 1995;1272(3):147–153. doi:10.1016/0925-4439(95)00079-8
   PubMed Web of Science ®Google Scholar
• Mu Q, Luo G, Wei J, et al. Apolipoprotein M promotes growth and inhibits apoptosis of colorectal cancer cells through upregulation of ribosomal protein S27a. Excli j. 2021;20:145–159. doi:10.17179/excli2020-2867
   PubMed Web of Science ®Google Scholar
• Luo J, Zhao H, Chen L, Liu M. Multifaceted functions of RPS27a: an unconventional ribosomal protein. J Cell Physiol. 2022. doi:10.1002/jcp.30941
   Web of Science ®Google Scholar
• Wang H, Zhao J, Yang J, et al. PICT1 is critical for regulating the Rps27a-Mdm2-p53 pathway by microtubule polymerization inhibitor against cervical cancer. Biochimica et Biophys Acta Mol Cell Res. 2021;1868(10):119084. doi:10.1016/j.bbamcr.2021.119084
   PubMed Web of Science ®Google Scholar
• Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021;22(7):1002–1013. doi:10.1016/s1470-2045(21)00199-6
   PubMed Web of Science ®Google Scholar
• Li Y, Gan Y, Liu J, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87. doi:10.1038/s41392-022-00902-6
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal Phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771. doi:10.1093/annonc/mdv237
   PubMed Web of Science ®Google Scholar
• Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511–1520. doi:10.4161/15592294.2014.983367
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao M, Cui L, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020;19(1):134. doi:10.1186/s12943-020-01256-9
   PubMed Web of Science ®Google Scholar
• Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets. 2013;17(1):29–41. doi:10.1517/14728222.2013.729042
   PubMed Web of Science ®Google Scholar
• Xiong W, Yang S, Zhang W, Chen Y, Wang F. MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1. Pharmazie. 2019;74(2):111–114. doi:10.1691/ph.2019.8756
   PubMed Web of Science ®Google Scholar
• Ye P, Xing H, Lou F, et al. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. Cancer Chemother Pharmacol. 2016;77(3):613–621. doi:10.1007/s00280-016-2979-9
   PubMed Web of Science ®Google Scholar
• Li J, Hu M, Liu N, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFβ axis. J Exp Clin Cancer Res. 2020;39(1):248. doi:10.1186/s13046-020-01720-w
   PubMed Web of Science ®Google Scholar
• Zhijun H, Shusheng W, Han M, Jianping L, Li-Sen Q, Dechun L. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016;37(8):10257–10267. doi:10.1007/s13277-016-4868-6
   PubMedGoogle Scholar
• Lamoine S, Cumenal M, Barriere DA, et al. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. Int J Mol Sci. 2021;23(1):98.
   PubMed Web of Science ®Google Scholar
• Ridinger J, Koeneke E, Kolbinger FR, et al. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. Sci Rep. 2018;8(1):10039. doi:10.1038/s41598-018-28265-5
   PubMed Web of Science ®Google Scholar
• Huang X, Bi N, Wang J, et al. Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas. J Oncol. 2021;2021:4936207. doi:10.1155/2021/4936207
   PubMed Web of Science ®Google Scholar
• Qiao Z, Ren S, Li W, et al. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun. 2013;434(1):95–101. doi:10.1016/j.bbrc.2013.03.059
   PubMed Web of Science ®Google Scholar
• Sun XX, DeVine T, Challagundla KB, Dai MS. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress. J Biol Chem. 2011;286(26):22730–22741. doi:10.1074/jbc.M111.223651
   PubMed Web of Science ®Google Scholar
• Wong JM, Mafune K, Yow H, et al. Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene. Cancer Res. 1993;53(8):1916–1920.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cai Y, Fu X, Chen L. High RPS27A Expression Predicts Poor Prognosis in Patients With HPV Type 16 Cervical Cancer. Front Oncol. 2021;11:752974. doi:10.3389/fonc.2021.752974
   PubMedGoogle Scholar
• Li H, Zhang H, Huang G, et al. Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells. J Exp Clin Cancer Res. 2022;41(1):33. doi:10.1186/s13046-021-02230-z
   PubMed Web of Science ®Google Scholar
• Rimal R, Desai P, Marquez AB, Sieg K, Marquardt Y, Singh S. 3-D vascularized breast cancer model to study the role of osteoblast in formation of a pre-metastatic niche. Sci Rep. 2021;11(1):21966. doi:10.1038/s41598-021-01513-x
   PubMed Web of Science ®Google Scholar
• Wang H, Feng J, Zhou T, Wei L, Zhou J. P-3F, a microtubule polymerization inhibitor enhances P53 stability through the change in localization of RPS27a. Int J Biochem Cell Biol. 2017;92:53–62. doi:10.1016/j.biocel.2017.09.010
   PubMed Web of Science ®Google Scholar